Genotype-phenotype relationships in an investigation of the role of proteases in abdominal aortic aneurysm expansion

British Journal of Surgery

Volumn 92, Issue 11, 2005, Pages 1372-1376

  Eriksson, P ^a   Jormsjo Pettersson S ^a   Brady, A R ^b   Deguchi, H ^a   Hamsten, A ^a   Powell, J T ^a,b  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GELATINASE A; GELATINASE B; MACROPHAGE ELASTASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEINASE; STROMELYSIN;

ABDOMINAL AORTA ANEURYSM; ADULT; AGED; ARTERY DIAMETER; ARTICLE; DISEASE COURSE; DNA DETERMINATION; FEMALE; FOLLOW UP; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MODEL; PATIENT MONITORING; PRIORITY JOURNAL; PROMOTER REGION; STATISTICAL SIGNIFICANCE; ULTRASOUND;

AGED; ANALYSIS OF VARIANCE; AORTIC ANEURYSM, ABDOMINAL; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PHENOTYPE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS);

EID: 27544496582     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.5126     Document Type: Article

References (19)

1. UK Small Aneurysm Trial Participants. Mortality results for randomised controlled trial of early elective surgery or ultrasonographic surveillance for small abdominal aortic aneurysms. Lancet 1998; 352: 1649-1655.
2. Lederle FA, Wilson SE, Johnson GR, Reinke DB, Littooy FN, Acher CW et al. for the Aneurysm Detection and Management Veterans Affairs Cooperative Study Group. Immediate repair compared with surveillance of small abdominal aortic aneurysms. N Engl J Med 2002; 346: 1437-1444.
3. Brown LC, Powell JT. Risk factors for aneurysm rupture in patients kept under ultrasound surveillance. UK Small Aneurysm Trial Participants. Ann Surg 1999; 230: 289-296.
4. Shah PK. Inflammation, metalloproteinases, and increased proteolysis: an emerging pathophysiological paradigm in aortic aneurysm. Circulation 1997; 96: 2115-2117.
5. Shibamura H, Olson JM, van Vlijmen-Van Keulen C, Buxbaum SG, Dudek DM, Tromp G et al. Genome scan for familial abdominal aortic aneurysm using sex and family history as covariates suggests genetic heterogeneity and identifies linkage to chromosome 19q13. Circulation 2004; 109: 2103-2108.
6. Jones K, Powell J, Brown L, Greenhalgh R, Jormsjo S, Eriksson P. Influence of 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene promoter on the incidence, growth and operative risk of abdominal aortic aneurysm. Eur J Vasc Endovasc Surg 2002; 23: 421-425.
7. Brady AR, Thompson SG, Fowkes FGR, Greenhalgh RM, Powell JT. Abdominal aortic aneurysm expansion: risk factors and time intervals for surveillance. Circulation 2004; 110: 16-21.
8. Lamblin N, Bauters C, Hermant X, Lablanche JM, Helbeque N, Amonyel P. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of anemysmal coronary artery disease. J Am Coll Cardiol 2002; 40: 43-48.
9. Zhang B, Dhillon S, Geary I, Howell WM, Iannotti F, Day INM et al. Polymorphisms in matrix metalloproteinase-1, -3, -9, and -12 genes in relation to subarachnoid hemorrhage. Stroke 2001; 32: 2198-2202.
10. UK Small Anemysm Trial Participants. The UK Small Aneurysm Trial: design, methods and progress. Eur J Vasc Endovasc Surg 1995; 9: 42-48.
11. Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99: 1788-1794.
12. Jormsjo S, Ye S, Moritz J, Walter DH, Dimmeler S, Zeiher AM et al. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 2000; 86: 998-1003.
13. Dawson SJ, Wiman B, Hamsten A, Green F, Humphries S, Henney AM. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhihitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268: 10739-10745.
14. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem 2001; 276: 7549-7558.
15. Ye S, Eriksson P, Hamsten A, Humphries SE, Kurkinen M, Henney AM. Progression of coronary atherosclerosis is associated with a common genetic variant of the human stromelysin-1 promoter which results in reduced gene expression. J Biol Chem 1996; 271: 13 055-13 060.
16. Eriksson P, Kallin B, van't Hooft FM, Bavenholm B, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-1855.
17. Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ et al. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 but not with risk of myocardial infarction in the ECTIM study. Etude Gas Temoins de Infarctus du Mycocarde. Thromb Haemost 1995; 74: 837-841.
18. Margaglione M, Cappucci G, d'Addedda M, Colaizzo D, Giuliani N, Vecchione G et al. PAI-1 plasma levels in a general population without clinical evidence of atherosclerosis: relation to environmental and genetic determinants. Arterioscler Thromb Vasc Biol 1998; 18: 562-567.
19. Jones KG, Brull DJ, Brown LC, Sian M, Greenhalgh RM, Humphries SE et al. Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 2001; 103: 2260-2265.